

Mechanistic Insights into *in vitro* DNA Adduction of OxaliplatinYea Seul Kim,^a Seonmi Shin,^a Minserk Cheong, and Sang Soo Hah*

Department of Chemistry and Research Institute for Basic Sciences, Kyung Hee University, Seoul 130-701, Korea

*E-mail: sshah@khu.ac.kr

Received April 27, 2010, Accepted May 3, 2010

Key Words: Oxaliplatin, DNA adduct, Mechanism of action

(*trans-R,R*)-1,2-Diaminocyclohexaneoxalatoplatinum(II) (oxaliplatin, also known as Eloxatine) is a novel platinum coordination compound, recently approved for the treatment of colorectal cancer, a major cause of cancer deaths worldwide, and has been licensed in the European Union since 1999, and in the United States since 2002 (structure shown in Figure 1).¹ Oxaliplatin has a broad spectrum of anticancer activity, and importantly, preclinical studies showed that oxaliplatin in combination with 5-fluorouracil has greater *in vitro* and *in vivo* anti-proliferative activity than either compound alone in several tumor models, including metastatic colorectal carcinoma.¹ Interestingly, the cytotoxicity effect of oxaliplatin is not affected in cisplatin-resistant cell lines, providing the first evidence of the absence of cross-resistance between oxaliplatin and cisplatin/carboplatin.²

Oxaliplatin has diaminocyclohexane (DACH) as a carrier




Figure 1. Chemical structures of cisplatin, carboplatin, and oxaliplatin.




Figure 2. Putative *in vivo* biotransformation pathways of oxaliplatin with low molecular weight endogenous compounds.

^aThese authors contributed equally to this work.

group and oxalato as a leaving group, and is generally assumed to exert the cytotoxicity effect by interaction with DNA to form monoadducts and intra- and interstrand diadducts, like other platinum-based anticancer drugs such as cisplatin and carboplatin.^{1,3} It has been known that a Pt-DNA level of ~ 200 fmol/10 μg of DNA reduces cell survival by 90%, and that a Pt-nucleobase binding ratio of *ca.* 1:250,000 is required to initiate apoptosis.⁴

Whereas the mechanisms of action for cisplatin and carboplatin are relatively well established,^{1,3} that for oxaliplatin remains uncertain; there are only a few previous studies on ring-opening reactions of oxaliplatin, reporting that the relative unstableness of oxaliplatin to hydrolysis and chloride substitution.⁵ In aqueous solution, it is reported that the oxalate ligand is detached in two steps, forming the oxalate monodentate complex and the dihydrated oxaliplatin complex.⁵ The ring-opening step has a half-life of 16.1 min ($7.17 \times 10^{-4} \text{ s}^{-1}$) and the loss of the oxalate ligand occurs with a half-life of 92.4 min ($1.25 \times 10^{-4} \text{ s}^{-1}$) at 37 °C, compared with overall half-lives of 268 h for carboplatin and 24 h for cisplatin in chloride-free phosphate buffer at pH 7 and 37 °C.^{5,6} Under *in vivo* conditions, oxaliplatin is known to undergo extensive biotransformation (see Figure 2 for putative biotransformation pathways of oxaliplatin with low molecular weight endogenous compounds). In plasma ultra-

filtrate from cancer patients, for example, biotransformation products with chloride, methionine and glutathione have been identified.⁷

We recently reported the use of an extremely sensitive detection method of accelerator mass spectrometry (AMS),⁸ to study the kinetics of oxaliplatin-DNA adduct formation in DNA.⁹ In this study, we describe a mechanistic refinement of the kinetics of hydration of the parent compound and subsequent covalent binding to DNA.

Salmon sperm DNA was incubated with [¹⁴C]oxaliplatin over time, and the fraction of the drug bound to the DNA in the form of both monoadducts and diadducts was experimentally determined and plotted as a function of time (Figure 3). The concentrations of oxaliplatin-DNA mono- and diadducts during the time course of the reaction allowed kinetic calculation of oxaliplatin binding to DNA. The radiocarbon content of the DNA displayed an exponential increase over the time course of the experiment, leading to determination of a kinetic constant k_{obs} to be $3.36 \times 10^{-6} \text{ s}^{-1}$ ($R^2 = 0.989$) by linear regression analysis.^{6(a)} Our results show that the reaction of oxaliplatin with DNA is very slow *in vitro*, suggesting that the DNA adduct formation *in vivo* may instead be forming with non-enzymatic biotransformation products of oxaliplatin (Figure 2). We attribute this kinetic profile to parameters defining the rate of oxaliplatin-DNA mono- and diadduct formation and by depletion




Figure 3. Ln(1-fraction of total radiocarbon) vs. time plot from experimental and theoretical data for *in vitro* reaction of oxaliplatin with DNA. The radiocarbon measured by accelerator mass spectrometry (AMS) due to oxaliplatin-DNA mono- and diadducts as a fraction of the total radiocarbon, represented by the symbol \blacklozenge . The line was fitted using linear regression analysis with $k_{\text{obs}} = 3.36 \times 10^{-6} \text{ s}^{-1}$ (solid line). These data were from our previously published paper (Ref. 9).




Figure 4. Proposed mechanism of action for oxaliplatin under the conditions in the study (the location of the ¹⁴C atom is asterisked). Based on the experimental data, a four consecutive irreversible pseudo-first-order reaction mechanism is assumed to be the major contributor for oxaliplatin-DNA monoadduct formation, followed by conversion to diadducts.

of the solution of oxaliplatin derivatives capable of reacting with DNA over time.

As depicted in Figure 4, the dominant mechanistic steps of oxaliplatin reacting with DNA likely include rate constants for: mono- and diaquation of the parent compound, k_1 and k_2 , respectively, formation of oxaliplatin-DNA monoadducts at purine nucleotides, k_3 , and diadduct formation, k_4 . It should be pointed out that in this mechanism chlorination reaction, backward reaction of the first ring-opening step, and acid dissociation of the oxalate monodentate complex are ignored in order to simply understand the mechanism of action for oxaliplatin in the reaction system employed, since 1) the buffer system employed is similar to one (50 mM NaCl, 10 mM HEPES buffer at pH 7.4 and 37 °C) in which oxaliplatin degradation was characterized to occur at a few percent per hour to form chlorinated species, although this chlorination reaction should not be ignored under *in vivo* conditions,¹⁰ 2) the series reaction of the hydrolysis of oxaliplatin is known to obey pseudo-first order kinetics and rate of the formation of diaquated species is very fast compared to that of the formation of diaquated cisplatin or carboplatin species (it should be noted, however, that the reverse reaction of oxaliplatin formation is fast when the oxalate monodentate complex is acidified, although at $\text{pH} \geq 12$ the conversion of the oxalate monodentate complex back to oxaliplatin is less than 1%),^{5(c)} and 3) the acid dissociation constant for the oxalate monodentate complex ($\sim 5.9 \times 10^{-8} \text{ s}^{-1}$) is approximately 1000-fold smaller than that for formation of diaquated oxaliplatin from the oxalate monodentate complex.^{5(b)} Moreover, it has been suggested that in order to react with DNA oxaliplatin should be activated *in vivo* to the diaquated oxaliplatin complex *via* either of two routes: by reaction with bicarbonate or phosphate followed by hydrolysis giving diaquated oxaliplatin complex or by reaction with chloride giving a dichloro complex which is subsequently hydrolysed to the diaquated species.⁷

An alternative mechanism could involve direct covalent binding of the monoaquated species to DNA, since the formation of monoadduct from the monoaquated oxaliplatin is likely to be kinetically important and the steady state concentration of this species can be greater than the steady state concentration of the diaquated oxaliplatin. However, we observed a substantial amount of non-covalently bound compound, possibly the diaquated +2 charged species, on the DNA especially at early time points, which could be removed by exposure of the solution to concentrated NaCl prior to DNA isolation (data not shown). In addition, rate of the formation of diaquated oxaliplatin is known to be very fast^{5(c)} and our data cannot be explained without an assumption that a ring-opened monoaquated oxali-

Table 1. Comparison of apparent rate constants for cisplatin and oxaliplatin adduction to DNA. Rate constants k_1 , k_2 , k_3 and k_4 for cisplatin stand for the rates for monoquation of cisplatin, monoadduct formation of monoquated species, monoquated species of monoadducts, and monoadduct-to-diadduct conversion, respectively, and rate constants for oxaliplatin stand for the rates for monoquation of the parent compound, diaquation of monoquated species, monoadduct formation of diaquated species, and monoadduct-to-diadduct conversion, respectively.

	cisplatin ^a	oxaliplatin
k_1	0.000102	0.000717 ^b
k_2	0.00196	0.000125 ^b
k_3	0.000092	~0.0000576 ^c
k_4	<i>n.d.</i>	~0.0000438 ^d

The unit for the kinetics constants is s^{-1} and *n.d.* represents *not determined*. ^aRef. 11, ^bRef. 5(c), ^cIn this study, ^dRef. 13, respectively.

platin derivative minimally or negligibly contributes to the oxaliplatin-DNA adduct formation, and thus that the four consecutive irreversible pseudo-first-order mechanism is a major contributor to oxaliplatin-DNA adduct formation. This interpretation is consistent with the presence of a substantial fraction of parent and monoquated compound early in the reaction, which are quantitatively converted to diaquated Pt(DACH) prior to covalent binding to DNA. From this point of view, oxaliplatin, like cisplatin, but differently from carboplatin, could be considered as a pro-drug, with hydrolysis being a key step. In fact, hydrolysis of cisplatin or oxaliplatin is extremely rapid, whereas it is slower for carboplatin.^{1,3,5}

Based upon the reported apparent rate constant values of k_1 ($7.17 \times 10^{-4} s^{-1}$) and k_2 ($1.25 \times 10^{-5} s^{-1}$),⁵ we estimated k_3 to be $(5.76 \pm 0.57) \times 10^{-6} s^{-1}$ (see Experimental Section for details). This value is approximately three-hundred-fold lower than reported for cisplatin (k_2 , $1.96 \times 10^{-3} s^{-1}$, Table 1),¹¹ explaining the lower reactivity of oxaliplatin than cisplatin in the literature.¹² The kinetic constant k_4 , however, could not be determined with our experimental data, since our method does not distinguish monoadducts from diadducts, although it may be assumed that k_4 for oxaliplatin monoadduct-to-diadduct conversion is likely close to that reported for diamminocyclohexanedichloroplatinum(II) [PtCl₂(DACH)] in the literature ($4.38 \times 10^{-5} s^{-1}$),¹³ since PtCl₂(DACH) should also form dihydrated oxaliplatin species prior to DNA adduction.

In conclusion, we refined the kinetics of oxaliplatin-DNA adduct formation, which may allow us to gain new mechanistic insights into *in vitro* DNA adduction of oxaliplatin, suggesting a mechanism of action for oxaliplatin *in vitro* (Figure 4), in which the leaving group is replaced by two water molecules in two consecutive steps forming the diaquated oxaliplatin complex, followed by the reaction with DNA to form monoadducts and by conversion to crosslinks. Table 1 summarizes the apparent rate constants for cisplatin- and oxaliplatin-DNA adduct formation *in vitro*, showing that the *in vitro* reaction of oxaliplatin with DNA is very slow compared to cisplatin, even if these values for cisplatin and oxaliplatin may not be directly compared. Overall, our kinetic study suggests that the DNA adduct formation of oxaliplatin *in vivo* may be forming with non-enzymatic biotransformation products of oxaliplatin, support-

ing the assumption that *in vivo*, oxaliplatin undergoes extensive nonenzymatic biotransformation and nucleophiles such as an endogenous bicarbonate and dihydrogen phosphate may displace the oxalate group forming unstable reactants which can be further hydrolyzed to aqua complexes, and that the aqua complexes are likely important for the cytotoxic effect of oxaliplatin, mediated by the formation of DNA adducts.

Experimental Section

To refine the kinetics of oxaliplatin-DNA adduct formation, we used the experimental data for *in vitro* DNA binding kinetics, previously described for oxaliplatin studies.⁹ Briefly, a mixture of [¹⁴C]oxaliplatin (GE Healthcare, Piscataway, NJ) and non-labeled oxaliplatin was prepared immediately prior to use and incubated with salmon sperm DNA (0.5 mg/mL) at 37 °C in 25 mM NaCl, 0.14 mM EDTA, 0.14 mM Tris-HCl, pH 7.4. This buffer system is similar to one (50 mM NaCl, 10 mM HEPES buffer at pH 7.4 and 37 °C) in which oxaliplatin degradation was characterized to occur at a few percent per hour to form chlorinated species.¹⁰ The initial concentration of oxaliplatin was 12.4 μg/mL (33.4 nmol, 33.4 μM), which contained 13.4 dpm (96.8 fmol) of [¹⁴C]oxaliplatin (77.6 μCi/mmol). Samples (200 μL) of the solution were taken at 11 time points up to 24 h (see Figure 3 for specific time points sampled), and were immediately adjusted to 0.5 M NaCl and frozen in liquid nitrogen. For AMS sample preparation, the samples were thawed on ice and the DNA was isolated at 4 °C by ethanol precipitation and air dried. The dried samples were redissolved in medium containing 50 mM sodium acetate, 10 mM MgCl₂, pH 5.5, as described for ethanol precipitation.¹⁴ Variance in DNA recovery, which ranged from 10 - 70 percent, did not influence the radiocarbon concentrations in the resulting AMS samples as evidenced by the high precision of the AMS measurements from triplicate experiments. The DNA was then converted to graphite, and analyzed for the ratio of ¹⁴C to total carbon by AMS, as previously described.^{3(a),9} All experiments were carried out in triplicate.

Kinetic calculation. When focusing on the carrier group (diamminocyclohexane or DACH) of oxaliplatin, there are at least five predominant forms of oxaliplatin derivatives in the reaction solution: Unreacted oxaliplatin (A), monoquated oxaliplatin (B), diaquated oxaliplatin (C), monofunctional oxaliplatin-DNA adduct (D), and difunctional oxaliplatin-DNA adduct (E). And because the concentration of the target sites in DNA is highly excess, the reaction kinetics can be assumed as the pseudo-first order (i.e. the concentration of the DNA target remains in constant vast excess), allowing for the determination of k_{obs} . The chlorination reaction of oxaliplatin is known to be negligibly slow,¹⁰ and the corresponding forms have been ignored in terms of kinetic consideration in this study, leading to a four-step consecutive irreversible pseudo-first-order reaction scheme. The overall rate constant k_{obs} can be used to calculate each rate constant based on the equation of $1/k_{obs} = 1/k_1 + 1/k_2 + 1/k_3 + 1/k_4$, which can be used to estimate the rate constant k_3 , when other rate constants k_1 , k_2 and k_4 are known.

Alternatively, k_3 can be estimated using the following equations where A_0 is the starting concentration of oxaliplatin, based

on the assumption of a four-step consecutive irreversible mechanism and the reported values of k_1 , k_2 and k_4 .^{3(a)}

$$[A] = A_0 e^{-k_1 t}$$

$$[B] = \frac{k_1 A_0}{k_2 - k_1} [e^{-k_1 t} - e^{-k_2 t}]$$

$$[C] = k_1 k_2 A_0 [e^{-k_1 t} / \{(k_2 - k_1)(k_3 - k_1)\} + e^{-k_2 t} / \{(k_1 - k_2)(k_3 - k_2)\} + e^{-k_3 t} / \{(k_1 - k_3)(k_2 - k_3)\}]$$

$$[D] = k_1 k_2 k_3 A_0 [e^{-k_1 t} / \{(k_4 - k_1)(k_3 - k_1)(k_2 - k_1)\} + e^{-k_2 t} / \{(k_4 - k_2)(k_3 - k_2)(k_1 - k_2)\} + e^{-k_3 t} / \{(k_4 - k_3)(k_2 - k_3)(k_1 - k_3)\} + e^{-k_4 t} / \{(k_3 - k_4)(k_2 - k_4)(k_1 - k_4)\}]$$

$$[E] = A_0 - [A] - [B] - [C] - [D]$$

Acknowledgments. Drs. Paul T. Henderson and Kenneth W. Turteltaub are acknowledged for helpful advice. This work was supported by Basic Science Program through the National Research Foundation of Korea (KRF) funded by the Ministry of Education, Science and Technology (MEST) (No. 2010-0015218).

References

- (a) Saunders, M.; Iveson, T. *Br. J. Cancer* **2006**, *95*, 131-138. (b) Graham, J.; Muhsin, M.; Kirkpatrick, P. *Nat. Rev. Drug Discov.* **2004**, *3*, 11-12. (c) Wang, D.; Lippard, S. J. *Nature Rev. Drug Discov.* **2005**, *4*, 307-320. (d) Jamieson, E. R.; Lippard, S. J. *Chem. Rev.* **1999**, *99*, 2467-2498.
- (a) Pendyala, L.; Creaven, P. J. *Cancer Res.* **1993**, *53*, 5970-5976. (b) Di Francesco, A. M.; Ruggiero, A.; Riccardi, R. *Cell Mol. Life Sci.* **2002**, *59*, 1914-1927.
- (a) Hah, S. S.; Stivers, K. M.; de Vere White, R. W.; Henderson, P. T. *Chem. Res. Toxicol.* **2006**, *19*, 622-626. (b) Chaney, S. G.; Campbell, S. L.; Bassett, E.; Wu, Y. *Crit. Rev. Oncol. Hematol.* **2005**, *53*, 3-11. (c) Desoize, B.; Madoulet, C. *Crit. Rev. Oncol. Hematol.* **2002**, *42*, 317-325. (d) Kartalou, M.; Essigmann, J. M. *Mutat. Res.* **2001**, *478*, 1-21. (e) Fuertes, M. A.; Alonso, C.; Perez, J. M. *Chem. Rev.* **2003**, *103*, 645-662.
- Oshita, F.; Eastman, A. *Oncol. Res.* **1993**, *5*, 111-118.
- (a) Summa, N.; Schiessl, W.; Puchta, R.; van Eikema, H. N.; van Eldik, R. *Inorg. Chem.* **2006**, *45*, 2948-2959. (b) Jerremalm, E.; Eksborg, S.; Ehrsson, H. *J. Pharm. Sci.* **2003**, *92*, 436-438. (c) Jerremalm, E.; Videhult, P.; Alvelius, G.; Griffiths, W. J.; Bergman, T.; Eksborg, S.; Ehrsson, H. *J. Pharm. Sci.* **2002**, *91*, 2116-2121.
- (a) Knox, R. J.; Friedlos, F.; Lydall, D. A.; Roberts, J. J. *Cancer Res.* **1986**, *46*, 1972-1979. (b) Canovese, L.; Cattalini, L.; Chessa, G.; Tobe, M. L. *J. Chem. Soc., Dalton Trans.* **1988**, *8*, 2135-2140.
- Graham, M. A.; Lockwood, G. F.; Greenslade, D.; Brienza, S.; Bayssas, M.; Gamelin, E. *Clin. Cancer Res.* **2000**, *6*, 1205-1218.
- (a) Hah, S. S. *J. Biomed. Sci.* **2009**, *16*, 54. (b) Hah, S. S. *Anal. Sci.* **2009**, *25*, 731-733. (c) Mundt, J. M.; Hah, S. S.; Sumbad, R. A.; Schramm, V.; Henderson, P. T. *Nucleic Acids Res.* **2008**, *36*, 228-236. (d) Hah, S. S.; Mundt, J. M.; Ubick, E. A.; Turteltaub, K. W.; Gregg, J. P.; Henderson, P. T. *Nucl. Instr. Methods Phys. Res. B* **2007**, *259*, 763-766. (e) Hah, S. S.; Kim, H. M.; Sumbad, R. A.; Henderson, P. T. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3627-3631.
- Hah, S. S.; Sumbad, R. A.; Vere White, R. W.; Turteltaub, K. W.; Henderson, P. T. *Chem. Res. Toxicol.* **2007**, *20*, 1745-1751.
- Jerremalm, E.; Hedeland, M.; Wallin, I.; Bondesson, U.; Ehrsson, H. *Pharm. Res.* **2004**, *21*, 891-894.
- Bancroft, D. P.; Lepre, C. A.; Lippard, S. J. *J. Am. Chem. Soc.* **1990**, *112*, 6860-6871.
- Woynarowski, J. M.; Chapman, W. G.; Napier, C.; Herzig, M. C. S.; Juniewicz, P. *Mol. Pharmacol.* **1998**, *54*, 770-777.
- Page, J. D.; Husain, I.; Sancar, A.; Chaney, S. G. *Biochemistry* **1990**, *29*, 1016-1024.
- Jennerwein, M. M.; Eastman, A.; Khokhar, A. *Chem. Biol. Interact.* **1989**, *70*, 39-49.